Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Long-term Tolerability
100%
Vorinostat
100%
Cutaneous T-cell Lymphoma
100%
Clinical Benefit
100%
Adverse Events
33%
Tolerability
16%
Long-term Safety
16%
Diarrhea
16%
Histone Deacetylase Inhibitor (HDACi)
16%
Drug Dependence
16%
Systemic Therapy
16%
Pulmonary Embolism
16%
Thrombocytopenia
16%
U.S. Food
16%
Mycosis Fungoides
16%
Safety Benefits
16%
Treatment Refractory
16%
Stable Disease
16%
Alopecia
16%
Rash
16%
Recurrent Disease
16%
Anorexia
16%
Median Time
16%
Nausea
16%
Subset Analysis
16%
Treatment Failure
16%
Orally Active
16%
Persistent Disease
16%
Previous Treatment
16%
Objective Response
16%
Stage IB
16%
Continuation Phase
16%
Heavily Pretreated Patients
16%
Cutaneous Manifestations
16%
Creatinine Phosphokinase
16%
Lymphoma Subtype
16%
Pharmacology, Toxicology and Pharmaceutical Science
Tolerability
100%
Vorinostat
100%
Cutaneous T Cell Lymphoma
100%
Adverse Event
33%
Syndrome
16%
Diarrhea
16%
Histone Deacetylase Inhibitor
16%
Phosphotransferase
16%
Recurrent Disease
16%
Alopecia
16%
Lung Embolism
16%
Creatinine
16%
Nausea
16%
Rash
16%
Anorexia
16%
Thrombocytopenia
16%
Mycosis fungoides
16%
Diseases
16%
Medicine and Dentistry
Vorinostat
100%
Cutaneous T Cell Lymphoma
100%
Adverse Event
33%
Phosphotransferase
16%
Histone Deacetylase Inhibitor
16%
Pulmonary Embolism
16%
Diarrhea
16%
Mycosis fungoides
16%
Recurrent Disease
16%
Systemic Therapy
16%
Exanthem
16%
Creatinine
16%
Nausea
16%
Thrombocytopenia
16%
Anorexia
16%
Alopecia Mucinosa
16%
Diseases
16%